Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration

Ueno, Taiki; Toi, M.; Koike, Masato; Nakamura, Shin; Tominaga, Teiji

doi:10.1054/bjoc.2000.1272

Cited by 222 publications

(214 citation statements)

References 39 publications

Supporting

Mentioning

194

Contrasting

Unclassified

Order By: Relevance

“…Elevated circulating TF levels in breast cancer have been described previously (Lwaleed et al, 1999;Ueno et al, 2000). Thrombocytosis has been described previously in cancer patients.…”

Section: Discussionmentioning

confidence: 80%

See 1 more Smart Citation

Early changes in the haemostatic and procoagulant systems after chemotherapy for breast cancer

et al. 2008

View full text Add to dashboard Cite

Venous thromboembolism (VTE) following breast cancer chemotherapy is common. Chemotherapy-induced alterations in markers of haemostasis occur during chemotherapy. It is unclear how rapidly this occurs, whether this is upregulated in patients developing VTE and whether changes predict for VTE. Markers of haemostasis, functional clotting assays and vascular endothelial growth factor were measured before chemotherapy and at 24 h, 4 days, 8 days and 3 months following commencement of chemotherapy in early and advanced breast cancer patients and in age-and sex-matched controls. Duplex ultrasound imaging was performed after 1 month or if symptomatic. Of 123 patients, 9.8% developed VTE within 3 months. Activated partial thromboplastin time (APTT), prothrombin time (PT), D-dimer, fibrinogen, platelet count, VEGF and fibrinogen were increased in cancer. Fibrinogen, D-dimer, VEGF and tissue factor were increased, at baseline, in patients subsequently developing VTE. D-dimer of less than 500 ng ml À1 has a negative predictive value of 97%. Activated partial thromboplastin time, PT and thrombin -antithrombin showed significantly different trends, as early as within 24 h, in response to chemotherapy in patients subsequently developing VTE. Markers of coagulation and procoagulants are increased, before chemotherapy, in patients who subsequently develop VTE. A group of patients at minimal risk of VTE can be identified, allowing targeted thrombopropylaxis to the higher risk group.

show abstract

“…Elevated circulating TF levels in breast cancer have been described previously (Lwaleed et al, 1999;Ueno et al, 2000). Thrombocytosis has been described previously in cancer patients.…”

Section: Discussionmentioning

confidence: 80%

“…Previous work has demonstrated a hypercoagulable state in breast cancer patients, with elevated markers of coagulation, including thrombin -antithrombin (TAT) (Falanga et al, 1998;Ozyilkan et al, 1998), fibrinogen (Miller and Heilmann, 1988), D-dimer (Blackwell et al, 2000;Oberhoff et al, 2000) and tissue factor (TF) (Lwaleed et al, 1999;Ueno et al, 2000).…”

mentioning

confidence: 99%

Early changes in the haemostatic and procoagulant systems after chemotherapy for breast cancer

et al. 2008

View full text Add to dashboard Cite

show abstract

“…The incubation of MDA-MB231 cancer cells with monocytes also induced an increase in cell-associated TF expression in both monocytes and MDA-MB231 cancer cells. TF, an initiator of blood coagulation cascade, is expressed in a wide variety of cancer cells and it is an independent prognostic indicator for overall survival in cancer patients (Ueno et al, 2000a). This increase in TF, because of cooperation between cancer cells and monocytes, could contribute to the deleterious effect of monocytes in cancer progression, as it plays an important role in cancer cell invasiveness.…”

Section: Cooperation Between Monocytes and Breast Cancer Cells E Blotmentioning

confidence: 99%

Cooperation between monocytes and breast cancer cells promotes factors involved in cancer aggressiveness

Blot

Chen

Vasse³

et al. 2003

Br J Cancer

View full text Add to dashboard Cite

In breast cancers, clinical symptoms of inflammation localised around the tumour at the time of diagnosis have been considered to have poor prognosis significance. In this study, the biological mechanisms responsible for the deleterious action of monocytes in cancer were investigated. The incubation of the breast-cancer-derived MDA-MB231 cells with monocytes resulted in an increase in factors involved in cell invasion (i.e. both cancer cells and monocytes-associated urokinase and Tissue Factor, and PAI-1 and MMP-9 secretion). Moreover, the functions of monocytes were also modified. Incubation of monocytes with MDA-MB231 cancer cells resulted in a downregulation in the secretion of the antiproliferative cytokine Oncostatin M, while the apoptotic factor TNF alpha was dramatically increased. However, MDA-MB231 cancer cells have been shown to be resistant towards the apoptotic action of TNF alpha. These findings demonstrate that incubation of MDA-MB231 cancer cells with monocytes induced a crosstalk, which resulted in an increased expression of factors involved in cancer cell invasiveness and in a modification of monocytes function against cancer cells, while inflammatory effects were increased. British Journal of Cancer (2003) The importance of stroma in cancer formation, growth and dissemination is now well established. In order to generate an invasive tumour, cancer cells need several mutations, but also formally necessitate sustenance from noncancer stroma cells, which supply and permit cancer cell growth and invasion. The presence of cytokines and inflammatory cells in cancer stroma, indicating defence reaction against cancer, generally correspond to a poor prognosis (Kleer et al, 2000). Furthermore, in breast cancer, initial presentation with clinical symptoms of inflammation indicates a particular aggressiveness and a worst prognosis than other breast cancers (Chevallier, 1993;Palangie et al, 1994;Kleer et al, 2000). However, the mechanisms leading to the pathological action of stroma-localised inflammatory cells in cancer, such as monocytes, remain poorly understood.The current study was undertaken to explore whether the factors of aggressiveness expressed by cancer cells were modified in the presence of monocytes. We also analysed the consequences of the incubation of monocytes with MDA-MB231 cancer cells on functions of monocytes both in the defence against tumour cells and in inflammatory functions. For this purpose, we tested the consequences of the interaction of the highly invasive breastderived MDA-MB231 cancer cells with monocytes with an in vitro system. MATERIAL AND METHODS Monocytes isolationA measure of 80 mm of blood from healthy volunteers was collected in sterile polypropylene tubes (Costar, Cambridge, MA, USA) containing 7.5 ml of ACD (38 mM citric acid, 74 mM citrate and 136 mM glucose). Platelet-rich plasma was removed by centrifugation (10 min, 100 g at room temperature). Mononuclear cells were collected after centrifugation (45 min, 400 g at room temperature) in Leucosep tubes (Costar, C...

show abstract

“…Attention has been focused on tissue factor (TF), a transmembrane receptor protein, which is not only the primary initiator of coagulation but also promotes tumor growth, angiogenesis, and metastasis [10][11][12]. Many tumor cells express high levels of TF and in several types of cancer, including breast cancer and pancreatic cancer, TF expression on tumor cells correlated with grade and tumor progression [13][14][15]. Only Kakkar et al [16] reported on the presence of circulating TF antigen in cancer patients, although the significance of this finding has not been clarified.…”

Section: Introductionmentioning

confidence: 99%

Microparticle‐associated tissue factor activity: a link between cancer and thrombosis?

Tesselaar¹,

Romijn²,

Linden³

et al. 2007

Journal of Thrombosis and Haemostasis

478

321

View full text Add to dashboard Cite

To cite this article: Tesselaar MET, Romijn FPHTM, van der Linden IK, Prins FA, Bertina RM, Osanto S. Microparticle-associated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost 2007; 5: 520-7.Summary. Background: Cancer, in particular mucinous adenocarcinoma, is associated with venous thromboembolism (VTE). Tissue factor (TF), initiator of coagulation, plays a central role in the paradigm that clotting and tumor growth form a vicious circle, in which hypercoagulability facilitates the aggressive biology of cancer and vice versa. Expression of TF in tumors is associated with poor differentiation and poor prognosis. Patient/methods: We investigated the association between clinically manifest VTE and procoagulant properties of circulating microparticles (MP) isolated from blood of unselected pancreatic and breast adenocarcinoma patients' consecutive subjects, who presented with ultrasound or CT-scan confirmed VTE, and healthy subjects. Results: Patients with disseminated breast and pancreatic cancer had significantly increased levels of MP-associated TF activity compared with healthy controls, subjects with idiopathic acute VTE and non-metastatic cancer patients. Patients with both high MP-associated TF-activity and MP-associated epithelial mucin (MUC1) had a lower survival rate at 3-9 months follow-up than those with low TFactivity and no MUC1 expression: the likelihood of survival was 0.42 (95% CI: 0.19-0.94) for an individual with these two predictor variables present, after adjustment for other factors (age cohort, type of cancer, VTE) in the Cox proportional hazards model. Conclusions: Our results suggest an important role for MP-associated TF and MUC1 in the pathogenesis of thrombosis in disseminated mucinous adenocarcinoma patients. Future studies should reveal the mechanism underlying the observed associations.

show abstract

Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration

Cited by 222 publications

References 39 publications

Early changes in the haemostatic and procoagulant systems after chemotherapy for breast cancer

Early changes in the haemostatic and procoagulant systems after chemotherapy for breast cancer

Cooperation between monocytes and breast cancer cells promotes factors involved in cancer aggressiveness

Microparticle‐associated tissue factor activity: a link between cancer and thrombosis?

Contact Info

Product

Resources

About